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ABSTRACT
Introduction: The aim of this study was to
evaluate the direct costs of patients with
diabetes ensured in a large health
maintenance organization, Maccabi Health
Services (MHS), in order to compare the
medical costs of these patients to the medical
costs of other patients insured by MHS and to
assess the impact of poorly controlled diabetes
on medical costs.
Methods: A retrospective analysis of patients
insured in MHS during 2012 was performed.
Data were extracted automatically from the
electronic database. A glycated hemoglobin
(HbA1c) level of [9% (75 mmol/mol) was
considered to define poorly controlled
diabetes, and that of\7% (53 mmol/mol) and
\8% (64 mmol/mol) to define controlled
diabetes for patients aged \75 and C75 years,
respectively. Multivariate analysis analyses were
done to assess factors affecting cost.
Results: Data on a total of 99,017 patients with
diabetes were obtained from the MHS database
for 2012. Of these, 54% were male and 72%
were aged 45–75 years. The median annual cost
of treating diabetes was 4420 cost units (CU),
with hospitalization accounting for 56% of the
total costs. The median annual cost per patient
in the age groups 35–44 and 75–84 years was
2836 CU and 7033 CU, respectively. Differences
between costs for patients with diabetes and
those for patients without diabetes was 85% for
the age group 45–54 years but only 24% for the
age group 75-84 years. Medical costs increased
similarly with age for patients with controlled
diabetes and those with poorly controlled
diabetes costs, as did additional co-morbidities.
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Costs were significantly impacted by kidney
disease. The costs for patients with an HbA1c
level of 8.0–8.99% (64–74 mmol/mol) and
9.0–9.99% (75–85 mmol/mol) were 5722 and
5700 CU, respectively. In a multivariate analysis
the factors affecting all patients’ costs were
HbA1C level, male gender, chronic diseases,
complications of diabetes, disease duration, and
stage of kidney function.
Conclusions: The direct medical costs of
patients with diabetes were significantly
higher than those of patients without diabetes.
The main drivers of these higher costs were
hospitalizations and renal function. In poorly
controlled patients the effect of HbA1c on costs
was limited. These findings suggest that it is cost
effective to identify patients with diabetes early
in the course of the disease.
Funding: The work was sponsored by internal
funds of the authors. Article processing charges
for this study was funded by Novo Nordisk.
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INTRODUCTION
Diabetes is one of the most commonly
occurring diseases in both developed countries
and in middle- and low-income countries.
According to the International’s Diabetes
Federation Diabetes Atlas [1, 2], during 2014
there were 387 million people living with
diabetes worldwide. One in 12 people around
the globe suffers from diabetes, and 50% of
afflicted patients are unaware of their disease
status. During 2014 there were 4.9 million
deaths from diabetes. According to the Israeli
Quality Indicators Program for Community
Health [3, 4], in 2013 there were 468,103
people aged 18 years or older (9.6% of the
adult Israeli population) diagnosed with
diabetes in Israel. In Israel as in other
countries in the world, there is documented
evidence that the prevalence of diabetes is on
the rise. This increase was particularly alarming
in 2011 and 2012, with the Israeli diabetes rate
increased from 9.1% of adults in 2011 to 9.5%
in 2012. The risk of diabetes increases with age,
reaching a peak in the age group of 75–84 years.
Only 64.3% of diabetes patients have controlled
diabetes, defined as a glycated hemoglobin
(HbA1c) level of [7% (53 mmol/mol) in the
age group 18–75 years and an HbA1C level of
[8% (64 mmol/mol) in the age group of
75 years and older. Of those individuals
diagnosed with diabetes, 31.6% have renal
injury (proteinuria or increased creatinine).
These numbers reflect the growing economic
burden on healthcare providers due to diabetes.
A recent systematic review of the global
evidence on the costs of type 2 diabetes
demonstrated that the costs of treating
diabetes increase over time and with disease
severity. Direct costs were found to be higher
than indirect costs and to be particularly high in
Western countries, such as the USA [2].
A Canadian study demonstrated that costs
were particularly high after the first year of
diagnosing diabetes and reached C$3785–3826
(Canadian dollars). These costs increased
substantially for older patients and for patients
who eventually died during the follow-up. After
accounting for baseline co-morbidities, costs
were primarily incurred through inpatient acute
hospitalizations, physician visits, prescription
medications, and assistive devices [5]. Similar
results have been found in other countries,
including the USA and Europe [6–11].
In order to decrease costs and improve
patients’ outcomes it is important to
understand the different effects of
co-morbidities, complication, and various
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interventions on the costs of treating patients
with diabetes. For example, chronic renal injury
significantly raises the costs of treating patients
with diabetes [12–14]. Also, it is important to
assess the relative impact of higher HbA1C
levels on medical costs as this guides the
choice of cost-effective interventions in the
spectrum of diabetic patients failing to achieve
their HbA1c goals.
Maccabi Healthcare Services (MHS) is the
second largest primary healthcare insurer and
provider in Israel. This health maintenance
organization (HMO) serves 25% of the total
population in Israel, with approximately 2
million members. In a study assessing diabetes
mellitus costs in MHS, diabetes accounted for
3.5% of the total medical costs for both men
and women [15].
The aim of this study was to evaluate the
direct costs of patients with diabetes ensured by
MHS in order to compare the medical costs of
these patients to those of other patients insured
by MHS and to identify the drivers of these
costs. In particular, we wanted to assess the
impact of poorly controlled diabetes on medical
costs as the Israeli Ministry of Health and the
National Quality Indicator Program pay
particular attention to patients with poorly
controlled diabetes, defined as an HbA1c level
of[9% (75 mmol/mol) [3, 4]. To do so we used
patient data complied in the electronic MHS
diabetes registry which contains information on




This retrospective study was conducted by
MHS after obtaining approval from the ethics
committee of MSH. It was performed in
accordance with the Helsinki Declaration.
This article does not contain any new studies
with human or animal subjects performed by
any of the authors. Since 1997, information on
member–MSH interactions (i.e., diagnoses,
visits to primary and secondary care
physicians, visits to outpatient clinics,
hospitalizations, laboratory tests, and
purchased and dispensed medications) have
been recorded in a large central computerized
database. Data on patients’ interactions with
MHS can be retrieved from this database. The
database includes information on
hospitalizations, emergency department visits,
physician visits, outpatient specialist visits,
home healthcare visits, purchases of
medications and other aids, laboratory tests,
imaging, and paramedical services such as
nursing care, physiotherapy, social workers,
and dietary consultations. Each individual has
a unique identification code in the system that
is valid for all encounters. All medical services
have a price tag that can be used to estimate
costs related to each patient or encounter.
Information on patients’ out of pocket
expenses, services that are fully paid for by
the patients themselves, and treatments
provided directly by the state, such as
primarily certain mental healthcare services
(e.g., hospitalization in psychiatric wards) and
costs of a hospital delivery, are also not
complied in the database. Indirect costs, such
as productivity losses owing to sick leave and
early retirement are also not included. Services
are automatically converted into monetary
terms by the MHS’ Financial Department [16].
To avoid disclosure of internal corporate
information, for this study all costs were
translated into internal resource cost units
(CU). CU were calculated as the actual cost
corrected to the formal pricing of medicines
and health technologies in Israel.
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The database includes several automatically
formulated registries, including a diabetes
registry. Patients are identified by an
automated database search; consequently, the
registry is not dependent on physicians
actively reporting on the patient to the
registry. These registries are routinely
validated by community physicians and other
healthcare workers. To be included in the
Diabetes registry patients had to have one or
more of the following criteria. The patient has
to be defined as diabetic according to the
criteria suggested by American Diabetes
Association: (1) presence of symptoms leading
to a diagnosis of diabetes; (2) a fasting plasma
glucose concentration of [126 mg/dl
(7.0 mmol/l) or casual (namely, any time of
day without regard to time since last meal)
plasma glucose concentration of 200 mg/dl
(11.1 mmol/l). In order to reach maximal
validity, we also included any patient who
met one of the following criteria: (1) purchased
at least two hypoglycemic medications or a
single insulin dose during one 6-month period;
(2) had an HbA1c measurement of at least
7.25% (55.7 mmol/mol). An HbA1c level of
6.5% (47.5 mmol/mol) was used as entry
criterion to the registry only when the
patient had been previously diagnosed as
diabetic. The codes employed do not
distinguish between insulin-dependent
diabetes mellitus (type 1) and
non-insulin-dependent diabetes mellitus (type
2). According to the 1994 Israel National
Health Act, MHS may not deny coverage to
applicants on any grounds, including age or
state of health. Thus, all sectors of the Israeli
population are represented in MHS, except for
young adults aged 18–21 years who, due to a
high percentage of them being enlisted in the
Israeli Defence Forces, are provided medical
care from this latter source.
Patients
To be included in these analyses patients had to
registered in the diabetes registry of MSH during
2012. Data extracted from the registry included
sociodemographic details, duration of diabetes,
drugs prescribed to treat diabetes,
comorbidities, HbA1c level, renal function,
and proteinuria. Patients were considered to
have poorly controlled diabetes if the HbA1c
level was [9% (75 mmol/mol). Controlled
diabetes was defined as an HbA1c level of\7%
(53 mmol/mol) for patients aged\75 years and
an HbA1c level of \8% (64 mmol/mol) for
patients aged C75 years within the past year.
Statistical Methods
Patient data were analyzed using descriptive
statistics and expressed. Continuous variables
were expressed as the mean and standard
deviation and dichotomous variables as the
number and percentage. Statistical significance
was set at p\0.05.
To assess determinants of costs, we
performed both a univariate and multivariate
analysis. The dependent variable was patient
costs. Candidate dependent variables were age,
gender, diabetes duration, HbA1c level, number
of co-morbidities, renal injury, and
medications. To enter a variable into the
multivariate regression model p was set at
\0.2. Significance was set at p\0.05. All
analyses were conducted using standard
statistical software (SPSS ver. 22; IBM Corp.,
Armonk, NY).
RESULTS
The diabetes registry included 99,017 patients,
of whom 54% (53,283) were male and 72% were
in the age group of 45–75 years. The mean and
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median costs of treating a patient with diabetes
for 1 year was 14,250 and 4420 CU, respectively.
The main driver of cost was hospitalization,
which accounted for 56% of the total spending
on patients with diabetes. Additional costs
included physician fees (11%) and all
medications for treating diabetes (16%). The
median annual medical costs for men and
women were 4046 and 4839 CU, respectively.
Costs increased significantly with age (Fig. 1).
For patients aged 35–44 years, the annual cost
per patient was 2836 CU as compared to 7033
CU for patients aged 75–84 years. Costs for
patients aged 25–34 years was 3315 CU per year.
The costs significantly increased with longer
period of time of diabetes diagnosis (Fig. 2),
with the costs of patients diagnosed within the
past 3 years being 3309 CU compared to 7975
CU for patients diagnosed[14 years ago. As can
be seen in Fig. 3, the differences between the
costs of patients with diabetes and the annual
median costs of all members in MHS decreased
with increasing age, with the difference being
86% for patients aged 45–54 years but only 14%
for patients aged 75–84 years.
To assess cost attributes in patients with poor
control of their diabetes we assessed various cost
attributes in patients with an HbA1c level of
[9% (75 mmol/mol) compared to patients with
an HbA1c level of \7% (53 mmol/mol) for
patients aged \75 years and with an HbA1c
level of\8% (64 mmol/mol) for patients aged
C75 years in the past year. As demonstrated in
Table 1, costs for both patients with controlled
diabetes and poorly controlled diabetes
increased by age in a similar fashion.
Additional co-morbidity increased costs in
both groups, but this variable was more
significant in patients with poorly controlled
diabetes. In patients with poorly controlled
diabetes, the median costs for those with no
Fig. 1 Median annual cost (in cost units (CU)] per
patient with diabetes by age distribution (in years).
Numbers at top of each bar Number of patients
Fig. 2 Median costs (in CU) of patients with diabetes in
relation to length of diabetes diagnosis (in years). Numbers
at top of each bar Number of patients
Fig. 3 Comparison of median costs (in CU) of patients
with diabetes to median costs of all customers of Maccabi
Healthcare Services clients by age (in years). Numbers at
top of each bar Number of patients
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co-morbidity, one co-morbidity, two
co-morbidities, and three or more
co-morbidities were 3240, 3716, 5130 and
11,555 CU, respectively; in comparison, in
patients with controlled diabetes, the
respective median costs were 2726, 3305,
4146, and 8170 CU. Surprisingly, HbA1c per se
had less effect than co-morbidity on patients’
costs, as seen in Table 2.
Kidney injury and kidney disease increased
significantly with age (Fig. 4). Costs were
significantly impacted by kidney disease,
particularly in patients with kidney injury
stage C and D (Fig. 5). Hospitalization was the
major contributor to costs in all stages of kidney
impairment, representing 53% of costs in stage
A, 60% in stage B, 66% in stage C, and 70% in
stage D.
In a multivariate regression model we
assessed the contribution of various patient
factors to costs. The independent factor was
patient costs per year. Factors that significantly
affected patients’ costs were HbA1C level, male
gender, any chronic disease, diabetes
complications, disease duration, and kidney
function stage. R2 was 17.2%.
DISCUSSION
In this analysis we assessed the cost of treating
patients with diabetes registered in a large
Maccabi Health Services database in Israel in
an attempt to understand the drivers of costs.
Our results demonstrate that MHS expenditure
was 86% higher in younger patients with
diabetes (age range 45–54 years) than in other
MHS clients. Differences in expenditure were
less striking with increasing patient age. These
results are in agreement with those of other
studies which demonstrated increased costs
incurred in treating patients with diabetes
[17–21]. A study assessing the economic
burden of diabetes in the USA in 2012 found
that patients with diabetes had 2.3-fold higher
medical expenditures than expenditures
expected in the absence of diabetes, with
inpatient care accounting for 43% of the
increased expenditure [17]. Chang et al. [18]








Median costs of patients
with poorly controlled
diabetes (CU)
Median costs of patients
with controlled
diabetes (CU)
15–24 9 (0.1) 5075 (7221) 2107 2684
25–34 114 (1.3) 6138 (8791) 2568 3705
35–44 950 (10.4) 7538 (14016) 3732 3028
45–54 2357 (25.9) 10,792 (25.555) 4202 2954
55–64 3029 (33.2) 13,626 (34,874) 5266 3493
65–74 1677 (18.4) 15,603 (26,930) 6992 4899
75–84 766 (8.4) 22,794 (35,435) 10,017 6796
85? 211 (2.3) 24,749 (35,618) 11,669 7783
CU Cost unit, SD standard deviation
a Standard deviation (SD) is given in parenthesis
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demonstrated that in Taiwan, where all
patients receive primary care through a
national health care system, patients with
diabetes have 1.4-fold higher medical costs
than patients without diabetes. These authors
also reported that in 2009, the medical costs of
outpatient management of diabetes accounted
for 18.5% of all outpatient expenditures.
Similar to our results, the cost of patients
with micro- and macrovascular complications
was fourfold higher than that of patients who
did not have complications associated with
diabetes [18]. In a study assessing medical costs
of patients with diabetes in Spain, the medical
care costs of patients with diabetes were 72.4%
higher than those for patients without diabetes
[19]. Based on patient data compiled in this
Spanish database, hospitalization of patients
Table 2 Patients costs in relation to glycated hemoglobin levels
HbA1c (%)a Number of patients Mean cost (CU)b Median cost (CU)
5.0–5.99 [31–41] 7935 16,206 (39,107) 4615
6.0–6.99 [42–52] 40,767 10,921 (25,414) 4095
7.0–7.99 [53–63] 22,479 12,237 (26,928) 4724
8.0–8.99 [64–74] 9040 14,242 (29,225) 5722
9.0–9.99 [75–85] 4338 13,654 (25,718) 5700
10.0–10.99 [85–95] 2289 13,068 (28,539) 5039
11.0–11.99 [96–106] 1279 13,856 (28,241) 5197
C12.0 [C107] 1207 13,754 (43,342) 4348
HbA1c Glycated hemoglobin
a HbA1c level in millimole/mole is given in square brackets
b SD in given in parenthesis



















Fig. 5 Medical costs (in CU; Y-axis of diabetes patients
with kidney injury stages A, B, C, and D registered in the
Maccabi Healthcare Services (MHS) database compared to
all Maccabi Healthcare Services (MHS) customers by age
(in years, X-axis)
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with diabetes accounted for 41.9% of the total
costs, generating a difference of 70% between
patients with diabetes and patients without
diabetes.
We demonstrated a significant impact of
co-morbidities on the medical costs of patients
with diabetes. Costs increased by threefold in
patients with diabetes with three co-morbidities
compared to patients with no co-morbidities in
well-controlled patients with diabetes. The
increase was 3.6-fold higher in patients with
uncontrolled diabetes. These results are
comparable to data from reported from other
countries [9, 10, 13, 17, 20–22].
Several factors emerged as main drivers of
cost in patients with diabetes, including
HbA1C level, male gender, any additional
chronic disease, complications associated with
diabetes, duration of diabetes, and kidney
function stage. In particular, the effect of
decreased renal function, proteinuria, and
dialysis were significant drivers of
expenditures that greatly surpassed the effect
of HbA1C level. Surprisingly, poorly controlled
diabetes had a lesser effect than expected on
patients’ costs. Menzin et al. [23] performed a
retrospective cohort study and found that the
odds of having at least one diabetes-related
hospitalization were not significantly
associated with higher mean HbA1c level—
with the exception of patients with a mean
HbA1c level of C10% (85.8 mmol/mol).
However, higher mean HbA1c levels were
associated with significantly higher estimated
hospitalization costs. The basic assumption is
that targeting this particular population of very
poorly controlled diabetes patients with a
HbA1c level of C9% (75 mmol/mol) is
cost-effective, whereas our data may suggest
that this is not necessarily so.
In our study population even a mild decrease
in renal function (defined as stage A) resulted in
a significant increase in a patient’s medical care
costs. This was true for all age groups. Costs
were much higher when the renal impairment
was defined as stage C and D. Ward et al. [7]
estimated that the event costs of proteinuria
and microalbuminuria were relatively low-cost
interventions ($109 and $79, respectively) while
end-stage renal disease cost $71,714. It has also
been demonstrated that medical costs increase
significantly for patients who progress from
stage A and B kidney impairment to stage C
and D [14]. However, our data appear to suggest
that even stage A renal impairment is a marker
of patients who are costly to the system beyond
the expected cost of diabetes or proteinuria per
se.
Kidney deterioration may be prevented not
only by decreasing HbA1c level but also by
other interventions, such as better control of
blood pressure, improving patients’ lipid
profiles, use of aspirin, smoking cessation,
and physical activity [24–27]. This may
explain why cost assessment goes beyond the
decrease of HbA1c level. Identifying these
patients in an early stage and implementing
multifaceted programs intervening in kidney
function decline may offer a significant
cost-effective intervention for patients with
diabetes. This benefit seems to be pronounced
in the younger population, as these patients
are expected to remain in MHS for many
additional years, with each year contributing
to increased costs. Further study is warranted
in this area.
The study has several limitations. This was a
retrospective observational study. Therefore, all
information relied on the completeness of the
medical records of routine clinical visits.
Clinical events may not have been captured in
full. It is possible that some co-morbidities were
not recorded and that laboratory data were
missing at various time-points.
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CONCLUSION
The results of this study show that direct costs
of patients with diabetes insured by MHS are
higher than the costs of patients without
diabetes insured by MHS. The major attributes
of costs were hospitalizations and renal disease.
In poorly controlled patients [HbA1c 8.0–8.99%
(64–74 mmol/mol) and patients with HbA1c
[9.0% (75 mmol/mol)] the effect of HbA1c
level on costs was limited. These findings
suggest that it is cost effective to identify
patients with diabetes early in the course of
the disease and to direct efforts at preventing
renal deterioration and hospitalizations.
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